VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+25.75%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$282M
AUM Growth
+$282M
(-58%)
Cap. Flow
-$337M
Cap. Flow
% of AUM
-119.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
2
Top Buys
No buys this quarter
Top Sells
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$321M |
| 2 |
Pharvaris
PHVS
|
$14.6M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
$1.12M |
| 4 |
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
|
$341K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $108M | 38.37% | 9,699,925 | – | – |
|
|
2
Pharvaris
PHVS
$1.39B
| $99.1M | 35.17% | 4,289,304 -630,200 | -13% | -$14.6M |
|
3
Harmony Biosciences
HRMY
$2.12B
| $34.8M | 12.33% | 1,035,396 | – | – |
|
|
SLRN
4
DELISTED
ACELYRIN
SLRN
| $26M | 9.23% | 3,852,470 | – | – |
|
|
ELEV
5
DELISTED
Elevation Oncology
ELEV
| $13.8M | 4.91% | 2,696,133 -218,122 | -7% | -$1.12M |
|
|
RYZB
6
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – | -5,158,162 | Closed | -$321M |
|
|
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| – | – | -2,759,791 | Closed | -$341K |
|